NEW YORK, April 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Endo International PLC (NASDAQ: ENDP), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), IDEXX Laboratories, Inc. (NASDAQ: IDXX), and Novo Nordisk A/S (NYSE: NVO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Salix Pharmaceuticals, Ltd. Analyst Notes
Salix Pharmaceuticals, Ltd. (Salix) posted on the Conferences and Meetings page of its website that it will participate at the following conferences during April-May 2014 - EASL: European Association for the Study of the Liver from April 9-13, 2014 in London, England; ACP: American College of Physicians from April 10-12, 2014 in Orlando, Florida; and APS: American Pain Society from April 30-May 3, 2014 in Tampa, Florida. The full analyst notes on Salix Pharmaceuticals, Ltd. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/SLXP/report.pdf
--
Endo International PLC Analyst Notes
On March 28, 2014. Endo Health Solutions Inc. (EHSI), a wholly-owned subsidiary of Endo International PLC, announced that it will commence offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022 issued by EHSI, which have an aggregate principal amount outstanding of $1.3 billion, for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 respectively, issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries. The Company informed that the offer, effective from March 27, 2014, will expire on April 23, 2014, 11:59 p.m. New York City time, unless extended or terminated. EHSI further said that the exchange offer will be conducted on a par-for-par basis, subject to downward adjustment for tenders submitted after 11:59 p.m., New York City time, on April 9, 2014. The full analyst notes on Endo International PLC are available to download free of charge at:
http://www.AnalystsReview.com/04072014/ENDPreport.pdf
--
ISIS Pharmaceuticals, Inc. Analyst Notes
On March 31, 2014, ISIS Pharmaceuticals, Inc (ISIS) reported final results from its Phase 2 study of ISIS-APOCIIIRx in patients with severely high triglycerides on stable doses of fibrates. According to ISIS, the study showed that those treated with ISIS-APOCIIIRx garnered average reductions of up to 71% in apolipoprotein C-III (apoC-III) and up to 64% in triglycerides, and average increases of up to 52% in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol. Additionally, the lipoprotein particle analysis showed significant dose-dependent reductions in the number of very low-density lipoprotein (VLDL) particles and significant increases in the number of HDL particles. Commenting on the results of this study, Joseph L. Witztum, M.D., Professor of Medicine at the University of California, San Diego, said, "In this new study, ISIS-APOCIIIRx was shown to robustly lower both plasma apoC-III and triglycerides, and raise HDL cholesterol levels, even in subjects who were already on standard doses of fibrate therapy. This ability of ISIS-APOCIIIRx to positively impact these parameters should significantly enhance the profile of the drug to treat patients with severely elevated triglycerides." The full analyst notes on ISIS Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/ISIS/report.pdf
--
IDEXX Laboratories, Inc. Analyst Notes
On March 27, 2014, IDEXX Laboratories, Inc. (IDEXX) announced the introduction of new diagnostics for safeguarding equine health. According to the Company, the new diagnostics will help equine veterinarians to quickly and proactively diagnose individuals or herds and enable them to more proactively manage the health of the horses under their care. The new diagnostics include three new RealPCR™ reproductive panels, the Strangles RealPCR™ Screen and a RealPCR test for Corynebacterium pseudotuberculosis, or pigeon fever. Commenting on the launch, Christian Leutenegger, Head of Molecular Diagnostics at IDEXX, remarked, "The equine RealPCR tests for reproductive health and pigeon fever and the expanded test option for strangles fill an important void in the diagnostic landscape for equine practitioners. Abortion in the equine industry is a sensitive topic; it leads to significant financial loss for mare owners." Leutenegger added, "The three new reproductive panels help veterinarians rapidly assess the infectious components in a lost pregnancy and our PCR strangles panel covers three important infectious organisms compared to just one. These advances, along with our pigeon fever test, improve the diagnostic ability of equine veterinarians to detect clinical infection earlier, better manage outbreaks and better educate clients to strengthen those relationships. " The full analyst notes on IDEXX Laboratories, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04072014/IDXX/report.pdf
--
Novo Nordisk A/S Analyst Notes
On April 2, 2014, shares of Novo Nordisk A/S (Novo) gained 0.71% to close the trading session at $45.53. Over the past three months of trading, Novo's shares jumped 23.99% over the Dow Jones Industrial Average Index, which gained 0.80% during the same period. The full analyst notes on Novo Nordisk A/S are available to download free of charge at:
http://www.AnalystsReview.com/04072014/NVO/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
